The Conversation (0)
July 27, 2025
Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)
INN Article Notification
29 August 2025
Appendix 4E and Preliminary Final Report
Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
29 July 2025
Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
10 June 2025
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
03 June 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
01 June 2025
RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
Radiopharm Theranostics (RAD:AU) has announced RAD Reports Positive Preclinical Lu177-B7H3-mAb DataDownload the PDF here. Keep Reading...
15 April
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness
Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure
Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the... Keep Reading...
15 April
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization (“CRO”) to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of... Keep Reading...
15 April
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Contracts signed for Animal Study GLP-1-A26-1 KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO")... Keep Reading...
14 April
Kailera, Alamar Target Billion-Dollar Valuations in Biotech Revival
Biotechnology initial public offerings (IPOs) are regaining momentum as easing market headwinds and an appetite for weight-loss drugs coax companies back to the public markets.On Monday (April 13) Reuters reported, that obesity drug developer Kailera Therapeutics and proteomics firm Alamar... Keep Reading...
13 April
Biotech and Pharma Market Update: Q1 2026 in Review
After a strong performance toward the end of 2025, the life science sector began the new year on a constructive note. Looking forward, signals in Q1 point to a market continuing to reward proof over promise. In an interview with the Investing News Network (INN), Eric Shrayer, partner and... Keep Reading...
08 April
Anthropic Inks US$400 Million Deal for AI Biotech Startup Coefficient Bio
AI developer Anthropic is acquiring New York-based biotech startup Coefficient Bio for approximately US$400 million, according to The Information.Founded just last fall and operating largely in stealth, Coefficient Bio will be absorbed directly into Anthropic’s healthcare life sciences... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00